EDMONTON, May 3 /CNW/ - BioMS Medical Corp. (TSX: MS), a leading
developer in the treatment of multiple sclerosis (MS), today announced that
following the fourth meeting of the independent Data Safety Monitoring Board
(DSMB), the Company has received a recommendation to continue its pivotal
phase II/III clinical trial for MBP8298 for the treatment of secondary
progressive multiple sclerosis. "The recommendation by the independent DSMB strengthens our confidence as
we move towards the completion of our pivotal trial," said Kevin Giese,
President of BioMS Medical.
